Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors. - Dumbrava EE; Shapiro GI; Parikh AR; Johnson ML; Tolcher AW; Thompson JA; El-Khoueiry AB; Vandross AL; Kummar S; Shepard DR; LeDuke K; Sheehan L; et al. (The New England journal of medicine, 2026)